Find the right asset, faster
Run diligence, map competitive landscapes, and prioritize assets with evidence, IP, and market context in one workflow.
From diligence to decision memo
See how EMET supports business development teams focused on diligence, competitive mapping, and asset prioritization.
Business development capabilities
Explore a range of sample prompts and representative outputs from EMET across the workflows below.
Scientific Due Diligence
Score STAT6 as a potential in-licensing target for atopic dermatitis - assess genetic evidence, disease expression, druggability, essentiality, and existing competitive compounds.
Competitive Pipeline Mapping
Map the full competitive pipeline for IL-33 pathway inhibitors across all indications - show me who is at what stage, and identify the white space.
Patent Landscape
Who holds the PRMT5 inhibitor IP, what inhibition mechanism dominates recent filings, and how has the competitive landscape shifted in the last 6 months?
Published Clinical Evidence Assessment
Assess the published clinical evidence for anti-TIGIT antibodies in NSCLC - summarize efficacy data across all published trials and generate a forest plot for ORR.
Asset Prioritization
We are evaluating 6 potential in-licensing targets. Plot them by scientific validation score vs. competitive intensity to prioritize which to advance to full diligence.
Frequently asked questions
Drug programs fail when biology is misunderstood. EMET exists to close that gap — before it closes your pipeline.
Start free trial